Exelixis stock has already delivered a 225.4% total return over the past 5 years, yet on the current checks it still screens as attractively priced rather than stretched.

• The 225.4% return over 5 years highlights how strongly Exelixis has rewarded long term holders, which raises the bar for any new upside case.
• Future revenue and cash flow growth from its oncology portfolio can support the current valuation. However, any setback in clinical progress or competitive pressure may quickly change how much investors are willing to pay for that growth.
• On Simply Wall St's broader valuation checks, Exelixis looks undervalued in 5 of 6 areas. This signals that the stock still leans cheap across multiple measures even after a strong run here.

The issue now is whether Exelixis offers enough valuation upside from here to justify fresh capital at around US$56 a share.

Is Exelixis a Bargain on Earnings?

The P/E ratio suits Exelixis because earnings are a key focus for many investors in profitable biotechs. At the current price, Exelixis trades on a P/E of about 16.9x, which is slightly below the wider biotech industry average of around 17.3x. It also sits well below the broader peer group average of roughly 28.3x.

The tailored fair P/E ratio for Exelixis is estimated at about 21.1x, which is higher than where the stock trades today. That fair multiple reflects what investors might typically pay for a company with Exelixis' profile, taking into account its growth outlook, margins, size and risk. The gap between the current P/E and this fair level suggests the market is applying a discount to the stock relative to what those factors might imply.

On the P/E multiple alone, Exelixis stock appears undervalued compared with both its fair ratio and many peers.

The Exelixis Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Exelixis valuation puzzle leaves off, because they set out what would need to happen with the company's growth, margins and earnings for the stock to be worth much more or much less than today. Each Narrative links a specific fair value to a particular story about Exelixis' potential catalysts and risks, so you can track over time which version of events seems to be unfolding on the Community page.

Exelixis community views sit far apart, with one camp focused on pipeline upside and another worried about pricing and concentration risk.

Bull case: 10% undervalued

"The company's robust cash flow, substantial balance sheet, and active share repurchase program provide significant financial flexibility for opportunistic business development and licensing deals..."

Bear case: 37% overvalued

"The increasing percentage of Exelixis' business coming from heavily discounted payer channels such as 340B which now make up over 24% of total volume compared to 20% a year earlier signals intensifying margin compression..."

Do you think there's more to the story for Exelixis? Head over to our Community to see what others are saying!

The Bottom Line

Exelixis still screens as undervalued on market multiples despite its strong 5 year return, which means the current price already reflects some caution around execution and competition. The key question is whether earnings can progress enough to close the gap between today’s P/E and the fair multiple implied by its fundamentals. If growth, margins and cash generation hold up against pricing pressure and pipeline risk, the current discount could look attractive. If those pressure points intensify, the apparent value support may fade quickly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.